logo
American West locks in offtake and $2M for emerging Canadian copper play

American West locks in offtake and $2M for emerging Canadian copper play

West Australian17-07-2025
American West Metals has cemented an off-take partner for its flagship Storm copper project in Nunavut, Canada, finalising key milestones in a transformative partnership with United Kingdom-based global metals trader Ocean Partners.
American West says its binding off-take agreement and funding commitments will de-risk the project's path to development and position Storm as a low-capex, high-return copper operation with significant resource upside across its sprawling 2200-square-kilometre tenure.
The company has completed a US$2 million (A$3.1 million) private placement with Ocean Partners to move the metal trading savants to a 9.4 per cent shareholding in American West.
The capital injection is paired with a binding off-take agreement securing all the project's copper, silver and gold production for a minimum of eight years.
Being well and truly invested in the outcome and outputs of Storm's development, Ocean Partners will also tin up a considerable 80 per cent of the initial capital - potentially US$40 million (A$61 million) - via a senior secured loan facility, contingent on bankable feasibility study results for Storm.
American West says the critical alliance is already bearing fruit for both parties, as Ocean Partners' technical advisors optimise processing workflows that will save plenty of legwork for the ongoing pre-feasibility study.
Located on Somerset Island, 120 kilometres south of Resolute Bay in Nunavut's Polaris mineral district, the Storm project is close to the Northwest Passage, a seasonal ice-free waterway historically used to ship concentrates from world-class zinc-lead mines such as Polaris and Nanisivik.
The company has established a 50-person camp to support its continuing ambitious exploration activities at the project, which has yielded an impressive mineral resource of 20.6 million tonnes grading 1.1 per cent copper and 3.8 grams per tonne (g/t) silver, equating to 229,000t of contained copper and 2.2 million ounces of silver.
With less than 5 per cent of the 110km prospective copper belt tested by the drill bit, American West is gearing up for a major 2025 drilling program targeting high-priority prospects to expand the resource base.
Storm's economic potential in a rising copper environment is plain to see. It is projecting a US$149 million (A$228 million) net present value and a 46 per cent internal rate of return (IRR) for a 10-year open-pit operation with a low initial capital cost of US$47.4 million (A$72.5 million).
By leveraging all its debt financing, the pre-tax IRR could soar to an impressive 135 per cent, with a three-year payback period and post-tax revenue of US$839 million (A$1.28 billion) at conservative copper prices well below today's Trump-imposed tariff market.
Adding to the momentum, American West's recent drilling campaigns have confirmed multiple high-grade discoveries, including a 47-metre copper sulphide intercept at its Cyclone Deeps deposit, reinforcing the potential for a stacked copper horizon beneath its flagship Cyclone deposit.
With a pipeline of prospects, including Blizzard and Tornado, waiting for drill testing, the company is poised to unlock further value along the 110km belt.
Partners Ocean Partners are already involved in metal trading operations in global copper centres such as Canada, Chile and China and have seen Storm's upside.
The finalised off-take deal and funding commitments align with rising global copper demand, driven by clean energy and electrification trends. Copper prices recently surpassed US$10,000 (A$15,300) per tonne.
As American West charges into the back half of its 2025 exploration and development season, Storm is shaping up as a low-risk, high-reward copper play. With robust economics, a de-risked funding strategy and a vast, underexplored copper belt in its portfolio, the company looks like it could be Canada's next copper player in a surging red metal price environment.
Is your ASX-listed company doing something interesting? Contact:
matt.birney@wanews.com.au
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ASX 200 dragged down by mining stocks on Thursday
ASX 200 dragged down by mining stocks on Thursday

Sky News AU

time2 hours ago

  • Sky News AU

ASX 200 dragged down by mining stocks on Thursday

Sky News Business Reporter Edward Boyd says the local market started down about one per cent at the open but fought back in the afternoon. 'The sell off was triggered by the sharp fall in Comex copper prices after Trump watered down his copper tariffs,' Mr Boyd said. "Mining stocks and energy companies heavily sold off; most sectors though were in the green, led by tech and discretionary retail.' The ASX 200 finished down just 0.16 per cent on Thursday.

NeuroScientific locks in deal to scale-up stem cell production
NeuroScientific locks in deal to scale-up stem cell production

Sydney Morning Herald

time2 hours ago

  • Sydney Morning Herald

NeuroScientific locks in deal to scale-up stem cell production

Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals has started transferring its patented StemSmart process to one of Australia's biggest and most experienced cell therapy manufacturers to scale up clinical-grade production. Queensland-based Q-Gen Cell Therapeutics will take over the manufacturing of StemSmart's specific mesenchymal stromal stem cells (MSC) from Royal Perth Hospital's Cell and Tissue Centre. NeuroScientific says the technology transfer will allow it to establish MSC manufacturing for its StemSmart infusions for further clinical trials and pursue commercial opportunities. The MSC technology was developed as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. 'This relationship will allow the company to scale the manufacturing of its StemSmart technology.' NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopogen. Isopogen had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen undertook manufacturing process development to scale up clinical-grade production of the StemSmart platform. Q-Gen, located in QIMR in Brisbane, has more than 25 years of experience in cell therapy manufacturing for industry. The laboratory specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control. NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith said: 'We are very pleased to be partnering with Q-Gen given their extensive experience in manufacturing, process development and GMP production of biologic products for clinical trials. This relationship will allow the company to scale the manufacturing of its StemSmart technology to address substantial market opportunities.' StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special medium, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes.

NeuroScientific locks in deal to scale-up stem cell production
NeuroScientific locks in deal to scale-up stem cell production

The Age

time2 hours ago

  • The Age

NeuroScientific locks in deal to scale-up stem cell production

Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals has started transferring its patented StemSmart process to one of Australia's biggest and most experienced cell therapy manufacturers to scale up clinical-grade production. Queensland-based Q-Gen Cell Therapeutics will take over the manufacturing of StemSmart's specific mesenchymal stromal stem cells (MSC) from Royal Perth Hospital's Cell and Tissue Centre. NeuroScientific says the technology transfer will allow it to establish MSC manufacturing for its StemSmart infusions for further clinical trials and pursue commercial opportunities. The MSC technology was developed as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. 'This relationship will allow the company to scale the manufacturing of its StemSmart technology.' NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopogen. Isopogen had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen undertook manufacturing process development to scale up clinical-grade production of the StemSmart platform. Q-Gen, located in QIMR in Brisbane, has more than 25 years of experience in cell therapy manufacturing for industry. The laboratory specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control. NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith said: 'We are very pleased to be partnering with Q-Gen given their extensive experience in manufacturing, process development and GMP production of biologic products for clinical trials. This relationship will allow the company to scale the manufacturing of its StemSmart technology to address substantial market opportunities.' StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special medium, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store